NeoImmuneTech, Inc. (KOSDAQ:950220)

South Korea flag South Korea · Delayed Price · Currency is KRW
468.00
-4.00 (-0.85%)
Apr 30, 2026, 3:30 PM KST
Market Cap46.67B -57.4%
Revenue (ttm)94.82M -44.3%
Net Income-31.80B
EPS-270.20
Shares Out98.87M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume924,520
Average Volume1,339,500
Open465.00
Previous Close472.00
Day's Range462.00 - 472.00
52-Week Range459.00 - 1,881.00
Beta0.37
RSI36.97
Earnings DateMay 14, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 52
Stock Exchange KOSDAQ
Ticker Symbol 950220
Full Company Profile

Financial Performance

In 2025, NeoImmuneTech's revenue was 94.82 million, a decrease of -44.35% compared to the previous year's 170.38 million. Losses were -31.80 billion, -22.23% less than in 2024.

Financial Statements